ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles(Queen Mary University of London), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Nicole N. Davarpanah(La Roche College), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Seattle Cancer Care Alliance), Maha Hussain(Northwestern University), Siamak Daneshmand(Unknown), Bernhard Zimmermann(Natera (United States)), David S. Shames(Gene Therapy Laboratory), Romain Banchereau(Kaiser Permanente San Francisco Medical Center), Kobe Yuen(La Roche College), Corey Carter(La Roche College), Zoe J. Assaf(Natera (United States)), Bernadett Szabados(Queen Mary University of London), Himanshu Sethi(Natera (United States)), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Alexey Aleshin(Natera (United States)), Jürgen E. Gschwend(Institut für Arbeitsmarkt und Berufsforschung), Peter Albers(Düsseldorf University Hospital), Maurizio Perdicchio(Roche (Switzerland)), Hiroyuki Nishiyama(University of Tsukuba), Joaquim Bellmunt(Dana-Farber Cancer Institute), Viraj Degaonkar(La Roche College), Xiaodong Shen(Fudan University), Carlos Bais(Eos Neuroscience (United States)), Shruti Sharma(Natera (United States)), Jingbin Zhang(Roche (Canada))
Cited by 603
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k